- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05943301
Study of the Impact of Non-pharmacological Techniques on Cognitive Complaints in Cancer Patients
July 4, 2023 updated by: Audrey Vanhaudenhuyse, University of Liege
Study of the Impact of Non-pharmacological Techniques (Self-hypnosis/Self-care) on the Well-being, Cognitive Complaints and Return-to-work in Cancer Patients
Cancer diagnosis generates a number of physical (pain, nausea and fatigue) and psychological implications for the patient.
At the psychological level, there are high levels of emotional distress (anxiety and depression) and cognitive impairments such as memory, attentional and information processing deficits, that can undermine the quality of life.
This last decade has shown great progress in cancer treatment allowing cancer patients, many of whom are of working age, to survive.
Unfortunately, cancer diagnosis and treatment induce various symptoms necessitating the patient to interrupt or quit his occupational status.
Hypnosis has been used in the past few years to treat these psychological and physical symptoms, be it at the moment of diagnosis, during and/or after the cancer treatments.
A large amount of studies has shown a positive effect of hypnosis in cancer patients notably upon anxiety, emotional distress and fatigue, three factors that can negatively affect cognitive functions.
The purpose of our study is to investigate the effect of a non-pharmacological treatment that combines self-hypnosis and self-care on well-being, cognitive complaints and return-to- work within a population of cancer patients.
Our hypothesis is that, by reducing emotional distress and fatigue, self-hypnosis/self-care will reduce the cognitive difficulties of cancer patients, foster return-to-work, and eventually improve the patients' global quality of life.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Liège, Belgium, 4000
- University of Liege
-
Liège, Belgium, 4000
- University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Major
- Fluency in French
- End of surgery and/or chimiotherapy and/or radiotherapy : 1-12 months.
- Cognitive complaints
Exclusion Criteria:
- Brain cancer
- Metastatic cancer
- Psychiatric disorder
- Neurologic disorder
- Neuropsychological assessment made within 3 months
- Drug addiction
- Alcoholism
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group
Self-hypnosis/self-care intervention : It is an 8-week 2 hour-session (one session per week) of self-hypnosis/ self-care learning.
Participants are given strategies to learn self-care (knowing your own needs, self-respect, communication, etc.), each strategie is discussed for participant to understand them and thus applie them correctly in daily living.
An hypnosis exercice is also realised at the end of each session.
|
Learning phase of self-hypnosis/self-care
|
|
No Intervention: Control group
The control goup has usual care and no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in subjective cognitive difficulties : Perceived cognitive impairments
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Perceived cognitive impairments" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009).
Scale ranging from 0 to 4 (0=never; 4=several times a day).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in subjective cognitive difficulties : Comments by others
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Comments by others" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009).
Scale ranging from 0 to 4 (0=never; 4=several times a day).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in subjective cognitive difficulties : Perceived cognitive abilities
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Perceived cognitive abilities" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009).
Scale ranging from 0 to 4 (0=not at all; 4=very much).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in subjective cognitive difficulties : Impact on quality of life
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on the perceived cognitive impairments will be assessed by means of the subtest "Impact on quality of life" of the Functionnal Assessment of Cancer Therapy-Cognitive Function (FACT-COG; Wagner et al., 2009).
Scale ranging from 0 to 4 (0=not at all; 4=very much).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitive difficulties : Verbal long term memory
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on verbal long term memory will be assessed by means the Buschke Selective Reminding Test (Buschke, 1973).
According to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitive difficulties : Attention
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on attention abilities will be assessed by means of the subtest "Phasic alertness" of the Test of Attentional Performance 2.3.1 (Zimmermann & Fimm, 2002).
Computerized test, according to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitive difficulties : Processing speed
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on processing speed abilities will be assessed by means of the first part of the Stroop test (Stroop, 1935).
According to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitvie difficulties : Inhibition
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on inhibition abilities will be assessed by means of the first part of the Stroop test (Stroop, 1935).
According to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitvie difficulties : mental flexibility
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on mental flexibility abilities will be assessed by means of the subtest "Flexibility" of the Test of Attentional Performance 2.3.1 (Zimmermann & Fimm, 2002).
Computerized test, according to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitvie difficulties : working memory
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on mental flexibility abilities will be assessed by means of the subtest "Working memory" of the Test of Attentional Performance 2.3.1 (Zimmermann & Fimm, 2002).
Computerized test, according to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in objective cognitvie difficulties : executive functions
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on executive functions will be assessed by means of the Wisconsin Card Sorting Test (David et al., 1948).
According to the sex and the subject's age, the test gives us a score and the norms.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Impact on return-to-work
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
For people who continued to work at time of recruitment, Work Design questionnaire will be administered Morgeson & Hymphrey, 2006).
Scale raging from 0 to 5 (0=not at all; 5=exactly).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in emtional distress : Anxiety
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on anxiety and despression will be assessed by means of the Hopsital Anxiety and Depression Scale (Zigmond & Snaith, 1983).
Scale ranging from 0 to 3 (0=never; 4=always).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in emtional distress : Depression
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on anxiety and despression will be assessed by means of the Hopsital Anxiety and Depression Scale (Zigmond & Snaith, 1983).
Scale ranging from 0 to 3 (0=alwaysr; 4=never).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in fatigue : General fatigue
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "general fatigue" of the Multidimensional Fatigue Inventory (Smets et al., 1995).
Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in fatigue : Physical fatigue
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "physical fatigue" of the Multidimensional Fatigue Inventory (Smets et al., 1995).
Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in fatigue : Mental fatigue
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "mental fatigue" of the Multidimensional Fatigue Inventory (Smets et al., 1995).
Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in fatigue : Motivational decrease
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on fatigue will be assessed by means of the subscale "motivational decrease" of the Multidimensional Fatigue Inventory (Smets et al., 1995).
Scale ranging from 1 to 4 (1=not agree at all; 4=agree completely).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in fatigue
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The impact of self-hypnosis/self-care on fatigue will be assessed by means of the Multidimensional Fatigue Inventory (MFI; Smets et al., 1995) and an 1-week agenda.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in fatigue : Weekly agenda
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
Qualitative questionnaire concerning the sleep habits of participants.
They have to give information concerning their sleeping habits.
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
|
Change in quality of life
Time Frame: T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
The improvement of quality of life will be assessed my means of the european Organization for Reasearch and Treatment of Cancer QLQ-C30 version 3.0 (E Aaronson et al., 1993).
Scale ranging from 1 to 4 (1=not at all; 4=excellent).
|
T1 (before the intervention), T2 (right after the intervention), T3 (3 months follow-up)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2019
Primary Completion (Actual)
July 30, 2020
Study Completion (Actual)
October 30, 2021
Study Registration Dates
First Submitted
February 11, 2019
First Submitted That Met QC Criteria
July 4, 2023
First Posted (Actual)
July 13, 2023
Study Record Updates
Last Update Posted (Actual)
July 13, 2023
Last Update Submitted That Met QC Criteria
July 4, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Metastatic Neoplasm
-
University of LiegeJules Bordet Institute; King Baudouin Foundation; Fonds National de la Recherche...CompletedNon-Metastatic NeoplasmBelgium
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Verastem, Inc.TerminatedMetastatic Cancer | Non Hematologic CancersUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisAstellas Pharma IncRecruitingMetastatic/Locally Advanced Non-Small-Cell Lung Cancer | Metastatic/Locally Pancreatic Ductal AdenocarcinomaFrance
-
National Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Unresectable Solid NeoplasmUnited States, Canada
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
SUNHO(China)BioPharmaceutical CO., Ltd.RecruitingAdvanced Malignant Neoplasm | Advanced or Metastatic Non-small Cell Lung CancerChina
-
M.D. Anderson Cancer CenterCompletedAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Carcinoma in the Liver | Metastatic Carcinoma in the Lung | Metastatic Malignant Neoplasm in the Thoracic CavityUnited States
-
M.D. Anderson Cancer CenterWithdrawnLocally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Bone
-
National Cancer Institute (NCI)Active, not recruitingNeuroendocrine Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic... and other conditionsUnited States
Clinical Trials on Self-hypnosis/self-care
-
University of LiegeUnknownComparison of Treatment for Chronic Non-malignant and Malignant PainBelgium
-
University of LiegeFondation BenoitUnknown
-
University of LiegeFree University of BrusselsCompleted
-
University of LiegeJules Bordet Institute; King Baudouin Foundation; Fonds National de la Recherche...CompletedNon-Metastatic NeoplasmBelgium
-
University of LiegeCompletedComparison of Different Treatment for Chronic Pain
-
University of LiegeCentre Hospitalier Universitaire de Liege; Fonds pour la Recherche Scientifique...Recruiting
-
University of LiegeRecruiting
-
Baylor UniversityUniversity of Michigan; National Center for Complementary and Integrative Health...CompletedBreast Cancer | Hot Flashes | Postmenopausal SymptomsUnited States
-
Baylor UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedMild Cognitive Impairment | Poor Quality SleepUnited States